和黄医药(00013)盘中大涨5.99%,引起市场关注。消息面上,公司同时传来两条利好消息。
首先,沃瑞沙和泰瑞沙联合治疗肺癌的新药上市申请已获国家药监局受理并纳入优先审评程序。这种创新疗法在临床前已展现出明显优势,获批上市将拓展和黄医药在肺癌治疗领域的产品线。
同时,和黄医药宣布以近45亿元人民币的代价出售上海和黄药业45%股权,以专注于创新药物研发业务。这一举措有助于和黄医药聚焦核心战略,提高资源使用效率,被视为公司转型创新发展的积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.